Keynote Address — Global CDMO Industry Outlook (Taiwan 2025)
In April 2025, I was invited to deliver the keynote address at the Global CDMO Leadership Conference in Taipei, organized by Taiwan’s Ministry of Economic Affairs (MOEA) in partnership with the Taiwan Medical and Biotech Industry Association (TMBIA), the Industrial Technology Research Institute (ITRI), and other ecosystem partners.
The conference convened leaders from global contract development and manufacturing organizations (CDMOs), investors, and policymakers to assess how geopolitical realignments, cost structures, and supply-chain diversification are reshaping advanced manufacturing.
My keynote focused on the macroeconomic and structural forces defining the CDMO sector worldwide:
The migration of biologics and cell-therapy manufacturing capacity from Western hubs to Asia.
The need for distributed, technology-integrated production networks that balance resilience with efficiency.
The changing role of national industrial policy in biotechnology manufacturing.
The shift from transactional outsourcing to strategic partnerships that fuse R&D and production.
The emergence of new capital models blending private equity, sovereign funding, and government innovation incentives.
The discussion emphasized that the CDMO industry has entered its globalization-of-infrastructure phase—where capabilities, data, and compliance must move as freely as intellectual property itself.
Coverage in Taiwanese and international outlets reflected the sector’s growing importance to Asia’s economic future. The MOEA highlighted the event as part of Taiwan’s strategy to solidify its place in the global life-sciences supply chain. GBI Monthly, GeneOnline, and TMBIA covered the keynote in the context of Taiwan’s ambition to lead next-generation biomanufacturing.
Read the full coverage →